Multi-Omics Analysis of the Therapeutic Value of MAL2 Based on Data Mining in Human Cancers

Jing Yuan1, Xiaoyan Jiang1, Hua Lan1

  • 1Department of Gynecology and Obstetrics, Third Xiangya Hospital, Central South University, Changsha, China.

Insights

T-cell differentiation protein 2 (MAL2) is a novel oncogene in ovarian cancer (OC). Its dysregulation impacts patient survival and drug sensitivity, and MAL2 deletion inhibits OC proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • T-cell differentiation protein 2 (MAL2) has emerged as a significant regulator in various cancers.
  • Understanding MAL2's role in pan-cancers, particularly ovarian cancer (OC), is crucial for developing targeted therapies.

Purpose of the Study:

  • To comprehensively analyze MAL2 expression, mutation status, and its functional impact on ovarian cancer.
  • To investigate MAL2's role in cancer progression, survival, and drug sensitivity across multiple cancer types.

Main Methods:

  • Utilized public databases (GEPIA, Kaplan-Meier plotter, COSMIC, cBioPortal, UCSC, GSCALite) for expression, survival, mutation, and drug sensitivity analysis.
  • Employed in vitro and in vivo assays, including qRT-PCR, western blotting, CRISPR/Cas9 gene knockout, proliferation, migration, invasion, and EMT marker analysis in OC cell lines.

Main Results:

  • MAL2 expression is dysregulated in multiple cancers and correlates with patient overall survival and drug sensitivity.
  • MAL2 knockout significantly inhibited proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in OC cell lines.
  • MAL2 acts as an oncogene, promoting OC proliferation, migration, and EMT.

Conclusions:

  • MAL2 is a novel oncogene in ovarian cancer that promotes proliferation, migration, invasion, and EMT.
  • MAL2 dysregulation is linked to patient outcomes and drug sensitivity in pan-cancers.
  • Targeting MAL2 may offer new therapeutic strategies for ovarian cancer treatment.